Dr. Behnam Sadeghi

Senior Researcher
Department of CLINTEC, Karolinska University Hospital, Sweden

Highest Degree
Ph.D. in Transplant Immunology from Karolinska Institutet, Stockholm, Sweden

My URL
https://livedna.org/98.5582

Share this Profile

Biography

Dr. Behnam Sadeghi is currently working as Senior Researcher at Karolinska University Hospital, Sweden. He obtained his Ph.D. in Transplant Immunology from Karolinska Institute, Stockholm, Sweden. His main area of interest related to Experimental and Clinical research. His area of expertise includes Stem Cell Transplantation, Graft Versus Host Diseases, Stem Cell, Mesenchymal Stromal Cells, Fetal Membrane Stromal Cells, Cell Therapy, Immunotherapy, T Cell Therapy, Regenerative Medicine, Translational Medicine, and Animal Models of Human Disease. He has published 3 book chapters, and 33 research papers in journals and meeting contributed as author/co-author.

Area of Interest:

Biomedical Sciences
Stem Cell Transplantation
Immunology
Regenerative Medicine
Translational Medicine

Selected Publications

  1. Sadeghi, B., E. Roshandel, A. Pirsalehi, S. Kazemi and G. Sankanian et al., 2021. Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. J. Cell Mol. Med., 25: 10554-10564.
    CrossRef  |  Direct Link  |  

  2. Ringdén, O., M. Remberger, J. Törlén, S. Finnbogadottir, B.M. Svahn and B. Sadeghi, 2021. Cytokine levels following allogeneic hematopoietic cell transplantation: A match-pair analysis of home care versus hospital care. Int. J. Hematol., 113: 712-722.
    CrossRef  |  Direct Link  |  

  3. Sadeghi, B., B. Ersmark, G. Moretti, J. Mattsson and O. Ringdén, 2020. Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells. Int. J. Hematol., 111: 591-594.
    CrossRef  |  Direct Link  |  

  4. Ringdén, O., B. Gustafsson and B. Sadeghi, 2020. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease. Front. Immunol., Vol. 11. 10.3389/fimmu.2020.567210.
    CrossRef  |  Direct Link  |  

  5. Kazemi, S., K. Parivar, N.H. Roudbari, P. Yaghmaei and B. Sadeghi, 2020. Growth kinetic comparison of human mesenchymal stem cells from bone marrow, adipose tissue and decidua. Med. Sci., 24: 223-234.
    Direct Link  |  

  6. Amin, R., R. He, D. Gupta, W. Zheng and M. Burmakin et al., 2020. The kidney injury caused by the onset of acute graft-versus-host disease is associated with down-regulation of αKlotho. Int. Immunopharmacol., Vol. 78. 10.1016/j.intimp.2019.106042.
    CrossRef  |  Direct Link  |  

  7. Ringden, O., M. Remberger, B. Gustafsson, G. Moretti, J. Mattsson, J. Winiarski and B. Sadeghi, 2019. The outcome of allogeneic hematopoietic stem cell transplantation for inherited diseases is influenced by HLA match, year of transplantation, and immunized female donor. Transplantation, 103: 1247-1252.
    CrossRef  |  Direct Link  |  

  8. Imani, M., S. Kazemi, M. Saviz, L. Farahmand, B. Sadeghi and R. Faraji-Dana, 2019. Morphological changes induced by extremely low-frequency electric fields. Bioelectromagnetics, 40: 375-390.
    CrossRef  |  Direct Link  |  

  9. Ringdén, O., M. Labopin, B. Sadeghi, A. Mailhol and D. Beelen et al., 2018. What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J. Intern. Med., 283: 166-177.
    CrossRef  |  Direct Link  |  

  10. Ringdén, O., B. Sadeghi, G. Moretti, S. Finnbogadottir and B. Eriksson et al., 2018. Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Int. J. Hematol., 107: 478-485.
    CrossRef  |  Direct Link  |  

  11. Ringden, O., A. Baygan, M. Remberger, B. Gustafsson and J. Winiarski et al., 2018. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl. Med., 7: 325-331.
    CrossRef  |  Direct Link  |  

  12. Ringdén, O., M. Labopin, C. Schmid, B. Sadeghi and E. Polge et al., 2017. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: A survey from the acute leukaemia working party of EBMT. Br. J. Haematol., 176: 431-439.
    CrossRef  |  Direct Link  |  

  13. Gustafsson, B., P. Frisk, A. Szakos, B. Sadeghi, O. Ringdén and B.M. Frost, 2017. Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. Pediatr. Transplant., Vol. 21. 10.1111/petr.12990.
    CrossRef  |  Direct Link  |  

  14. Baygan, A., W. Aronsson-Kurttila, G. Moretti, B. Tibert and G. Dahllöf et al., 2017. Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis. Front. Immunol., Vol. 8. 10.3389/fimmu.2017.00795.
    CrossRef  |  Direct Link  |  

  15. Abedi-Valugerdi, M., J. Wolfsberger, P.R. Pillai, W. Zheng, B. Sadeghi, Y. Zhao and M. Hassan, 2016. Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. Int. Immunopharmacol., 40: 41-49.
    CrossRef  |  Direct Link  |  

  16. Sadeghi, B., Y. Heshmati, B. Khoein, H. Kaipe, M. Uzunel, J. Walfridsson and O. Ringdén, 2015. Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo. Cytotherapy, 17: 1732-1745.
    CrossRef  |  Direct Link  |  

  17. Ringden, O., M. Solders, T. Erkers, S. Nava and P. Molldén et al., 2015. Placenta-derived decidual stromal cells for graft-versus-host disease, hemorrhaging, and toxicity after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., Vol. 21. 10.1016/j.bbmt.2014.11.209.
    CrossRef  |  Direct Link  |  

  18. Moll, G., L. Ignatowicz, R. Catar, C. Luecht and B. Sadeghi et al., 2015. Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev., 24: 2269-2279.
    CrossRef  |  Direct Link  |  

  19. Kaipe, H., L.M. Carlson, T. Erkers, S. Nava and P. Molldén et al., 2015. Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. Stem Cells Dev., 24: 1471-1482.
    CrossRef  |  Direct Link  |  

  20. Ringdén, O., M. Uzunel, B. Sadeghi, M. Solders, M. Uhlin, J. Mattsson and M. Remberger, 2014. decreased risk of acute graft-versus-host disease using reduced intensity conditioning compared to myeloablative conditioning is independent of donor-recipient t-cell chimerism. J. Transplant Technol. Res., Vol. 4. 10.4172/2161-0991.1000142.
    CrossRef  |  Direct Link  |  

  21. Kaipe, H., T. Erkers, B. Sadeghi and O. Ringdén, 2014. Stromal cells-are they really useful for GVHD? Bone Marrow Transplant., 49: 737-743.
    CrossRef  |  Direct Link  |  

  22. Sadeghi, B., H. Al-Chaqmaqchi, S. Al-Hashmi, D. Brodin and Z. Hassan et al., 2013. Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target? Bone Marrow Transplantation, 48: 284-293.
    CrossRef  |  PubMed  |  Direct Link  |  

  23. Sadeghi, B. and O. Ringden, 2013. Mesenchymal Stem Cells for Graft Versus Host Disease in Experimental Animal Models. In: Stem Cell Dependent Therapies, Gross, G. and T. Haupl (Eds.). De Gruyter, Berlin.

  24. Ringden, O., B. Sadeghi, 2013. Mesenchymal Stem Cells for Clinical/Therapeutic Interventions of Graft Versus Host Disease. In: Stem Cell Dependent Therapies Gross, G. and T. Haupl (Eds.). De Gruyter, Berlin.

  25. Hashmi, S.A., B. Sadeghi, Z. Hassan, M. Abedi-Valugerdi and M. Lindskog et al., 2013. Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion. Bone Marrow Transplantation, 48: 843-848.
    CrossRef  |  PubMed  |  Direct Link  |  

  26. Al-Chaqmaqchi, H., B. Sadeghi, M. Abedi-Valugerdi, S. Al- Hashmi, M. Fares and R. Kuiper, et al., 2013. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLOS ONE, 10.1371/journal.pone.0060367.
    CrossRef  |  PubMed  |  Direct Link  |  

  27. Ringden, O. and B. Sadeghi, 2012. Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning? Biol. Blood Marrow Transplant, 18: 1615-1617.
    CrossRef  |  PubMed  |  Direct Link  |  

  28. Al-Hashmi, S., P.J.M. Boels, F. Zadjali, B. Sadeghi and J. Sallstrom et al., 2012. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS ONE, 10.1371/journal.pone.0030897.
    CrossRef  |  PubMed  |  Direct Link  |  

  29. Sadeghi, B., H. Hagglund, M. Remberger, S. Al-hashmi, Z. Hassan, M. Abedi-Valugerdi and M. Hassan, 2011. Glucosamine activates T lymphocytes in healthy individuals and may induce GVHD/GVL in stem cell transplanted recipients. Open Transplant. J., 5: 1-7.
    Direct Link  |  

  30. D'Arcy, P., S. Brnjic, M.H. Olofsson, M. Fryknas and K. Lindsten et al., 2011. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med., 17: 1636-1640.
    CrossRef  |  PubMed  |  Direct Link  |  

  31. Al-Hashmi, S., Z. Hassan, B. Sadeghi, B. Rozell and M. Hassan, 2011. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. Int. J. Clin. Exp. Pathol., 4: 596-605.
    PubMed  |  Direct Link  |  

  32. Sadeghi, B., S. Al-Hashmi, Z. Hassan, B. Rozell and H. Concha et al., 2010. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin. Dev. Immunol., 10.1155/2010/142943.
    CrossRef  |  PubMed  |  Direct Link  |  

  33. Sadeghi, B., N. Aghdami, Z. Hassan, M. Forouzanfar, B. Rozell, M. Abedi-Valugerdi and M. Hassan, 2008. GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant., 42: 807-818.
    CrossRef  |  PubMed  |  Direct Link  |  

  34. Sadeghi, B., M. Jansson, M. Mints, Z. Hassan, M. Abedi-Valugerdi and M. Hassan, 2008. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant., 41: 895-904.
    CrossRef  |  PubMed  |  Direct Link  |  

  35. Mints, M., M. Jansson, B. Sadeghi, M Westgren, M. Uzunel, M. Hassan and J. Palmblad, 2008. Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient. Human Reproduct., 23: 139-143.
    PubMed  |  

  36. Masoompour, S.M., M.H. Bagheri, B.A. Haghighi, Y.A. Novitsky and B. Sadeghi et al., 2008. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer: A phase 2 clinical study. DARU, 16: 31-34.
    Direct Link  |  

  37. Khorshid, H.R.K., B. Sadeghi, R. Heshmat, M. Abdollahi, P. Salari, B. Farzamfar and S.H. Madani, 2008. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARSTM). DARU J. Pharm. Sci., 16: 20-24.
    Direct Link  |  

  38. Said, R., M. Abdel-Rehim, B. Sadeghi, S. Al-Hashemi, Z. Hassan and M. Hassan, 2007. Cyclophosphamide Pharmacokinetics in Mice: A Comparison between retro orbital sampling versus serial tail vein bleeding. Open Pharmaco. J., 1: 30-35.
    Direct Link  |  

  39. Shiva, F., M. Nasiri, B. Sadeghi and M. Padyab, 2003. Effects of passive smoking on common respiratory symptoms in young children. Acta Paediatr, 92: 1394-1397.
    CrossRef  |  PubMed  |  Direct Link  |  

  40. Haidari, M., E. Javadi, B. Sadeghi, M. Hajilooi and J. Ghanbili, 2001. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin. Biochem., 33: 309-315.
    CrossRef  |  PubMed  |  Direct Link  |  
Member since October, 2015